Abstract: A P2Y12 receptor antagonist containing a guanidyl, and a preparation method and the use thereof. In particular, the present disclosure provides a pyridazinone-guanidine compound that is a compound of structural formula (I), or a stereoisomer of the above-mentioned compound, a pro-drug thereof, a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable solvate thereof. Such a compound has multiple pharmacological activities, especially has an inhibitory effect on platelet aggregation, and can be used for preparing an anti-platelet aggregation pharmaceutical composition.
Type:
Grant
Filed:
November 25, 2020
Date of Patent:
November 29, 2022
Assignee:
Anhui New Star Pharmaceutical Development Co., Ltd
Abstract: The present invention relates to compounds (I) capable of inhibiting the Mst1/2 protein kinase activity, a preparation method therefor, a pharmaceutical composition comprising the compounds, and uses of the compounds and the pharmaceutical composition comprising the compounds in the preparation of drugs for prompting repair and regeneration of tissues and organs, prompting stem cell proliferation and somatic cell dedifferentiation, immunosuppression, and preventing or treating diseases related to nervous disorders and local ischemia.
Type:
Grant
Filed:
March 2, 2017
Date of Patent:
April 13, 2021
Assignee:
Anhui New Star Pharmaceutical Development Co., Ltd.
Abstract: The present invention relates to compounds (I) capable of inhibiting the Mst1/2 protein kinase activity, a preparation method therefor, a pharmaceutical composition comprising the compounds, and uses of the compounds and the pharmaceutical composition comprising the compounds in the preparation of drugs for prompting repair and regeneration of tissues and organs, prompting stem cell proliferation and somatic cell dedifferentiation, immunosuppression, and preventing or treating diseases related to nervous disorders and local ischemia.
Type:
Application
Filed:
March 2, 2017
Publication date:
April 16, 2020
Applicant:
Anhui New Star Pharmaceutical Development Co., Ltd .
Abstract: The present invention provides a Bruton's tyrosine kinase inhibitor, which is a compound represented by formula (I) or a pharmaceutically acceptable salt, solvate, ester, acid, metabolite or prodrug thereof. The present invention also provides a pharmaceutical composition comprising the compound. The present invention also provides a method and use of using the Bruton's tyrosine kinase inhibitor to inhibit the tyrosine kinase activity or treat diseases, disorders or symptoms benefiting from the inhibition of the Bruton's tyrosine kinase (Btk) activity.
Type:
Grant
Filed:
January 27, 2015
Date of Patent:
November 14, 2017
Assignees:
HEFEI INSTITUTES OF PHYSICAL SCIENCE, CHINESE ACADEMY OF SCIENCES, ANHUI NEW STAR PHARMACEUTICAL DEVELOPMENT CO., LTD.
Abstract: The invention discloses a novel intermediate for preparing tapentadol and analogs thereof, wherein the structural formula is shown as formula I or II, and the groups are defined as the specification. The invention further discloses a method for preparing the novel intermediate and use of the intermediate for preparing tapentadol and analogs thereof. The invention can remarkably improve the product yield and quality of tapentadol, reduce the production cost, and simplify the production procedure. The preparation process is environment friendly, thus more suitable for the requirements of industrial production.
Type:
Grant
Filed:
August 25, 2014
Date of Patent:
January 31, 2017
Assignee:
ANHUI NEW STAR PHARMACEUTICAL DEVELOPMENT CO., LTD.
Inventors:
Ziao Xu, Yuanhai Zhao, Degang Li, Xiaoxiang Li
Abstract: The invention discloses a novel intermediate for preparing tapentadol and analogues thereof, wherein the structural formula is shown as formula I or II, and the groups are defined as the specification. The invention further discloses a method for preparing the novel intermediate and use of the intermediate for preparing tapentadol and analogues thereof. The invention can remarkably improve the product yield and quality of tapentadol, reduce the production cost, and simplify the production procedure. The preparation process is environment friendly, thus more suitable for the requirements of industrial production.
Type:
Grant
Filed:
July 29, 2011
Date of Patent:
October 7, 2014
Assignee:
Anhui New Star Pharmaceutical Development Co., Ltd.
Inventors:
Ziao Xu, Yuanhai Zhao, Degang Li, Xiaoxiang Li
Abstract: The invention relates to a retinoid derivative and pharmaceutical composition and use thereof. The compound of the invention is capable of preventing or treating hematological tumors, such as acute leukemia, chronic leukemia, multiple myeloma and lymphoma, solid tumors, such as liver cancer, rectal cancer, mammary cancer and esophagus cancer, and skin disorders, such as psoriasis and acne.
Type:
Grant
Filed:
May 31, 2009
Date of Patent:
February 7, 2012
Assignees:
Anhui Medical University, Anhui New Star Pharmaceutical Development Co., Ltd.
Inventors:
Feihu Chen, Jingbo Shi, Yuan Wang, Jun Li, Juan Shen, Jingjing Ruan, Fanrong Wu
Abstract: The invention relates to a retinoid derivative and pharmaceutical composition and use thereof. The compound of the invention is capable of preventing or treating hematological tumours, such as acute leukemia, chronic leukemia, multiple myeloma and lymphoma, solid tumours, such as liver cancer, rectal cancer, mammary cancer and esophagus cancer, and skin disorders, such as psoriasis and acne.
Type:
Application
Filed:
May 31, 2009
Publication date:
March 31, 2011
Applicants:
ANHUI MEDICAL UNIVERSITY, Anhui New Star Pharmaceutical Development Co., Ltd
Inventors:
Feihu Chen, Jingbo Shi, Yuan Wang, Jun Li, Juan Shen, Jingjing Ruan, Fanrong Wu